Kamada Ltd.

Greetings and welcome to the Commodore Ltd. second quarter 2026 earnings conference call. At this time, our participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference over to Brian Ritchie, Managing Director of LifeSci Advisors. Please go ahead, sir.

Thank you, Operator. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Comida are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier today, Comida announced its financial results for the three and six months ended June 30, 2026. If you have not received this news release, Please go to the Investors page of the company's website at www.commoda.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Commoda. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's forms 20F and 6K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Wednesday, August 12th, 2026. Comida undertakes no obligation to revise, Thank you, Brian. My thanks also to investors and analysts for your interest in Commodore and for participating in today's call.

I am pleased to report that we continue to execute on our strategic multi-year growth plan delivering record high operational and financial performance during the first half of 2026 with strong double-digit growth in revenues and adjusted EBITDA for both the six-month and second-quarter reporting periods. Before proceeding to the specifics, I would like to point out that when examining and analyzing the company performance during recent months, and without future binary events, it's clear that the company growth strategy model based on our well-defined four growth pillars is working effectively. We are seeing growth and improvement across all financial metrics including expanded sales and revenues, operational synergies and disciplined management of expenses, enhanced profitability and EBITDA and a strengthened ability to generate cash from operations. It's important to note that the significant growth we are currently experiencing is driven solely by our existing commercial product portfolio, organic growth, and that once we execute the acquisitions and M&A transactions that are also part of a strategic plan, this growth will accelerate even farther, resulting in enhanced financial metrics. With that said, let's move on now to our first six months' performance. Total revenues were a record high of $100.2 million for the first half, an increase of approximately 13% year over year. Adjusted EBITDA was a record high of $25.7 million, up 14% year over year, and representing a notable 26% margin of revenues. For the second quarter of the year, total revenues were $54.9 million. The strongest in our history, representing a 23% year-over-year increase. Adjusted EBITDA was $14.1 million, up 29% year-over-year, and representing a 26% margin of revenue. Net income for the first half was $13.4 million, and 18% up year-over-year. Second quarter net income was $9.3 million, and more. Our revenues and adjusted EBITDA for the first six months of the year represent approximately 50% of our 2026 annual guidance. Based on our first half performance, we are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively representing a 12% and 23% growth when comparing 2026 guidance midpoints to 2025 results. As described on previous calls, we continue to be focused on our four growth drivers on a path for delivering continuous double-digit profitable annual growth. We are focused on continuing sales growth of our entire commercial portfolio, including our six FDA-approved specialty plasma-derived products. In our distribution segment, growth is supported by the launch of additional biosimilar products in the Israeli market, as well as the expansion of the distribution business to the MENA region, which is ongoing with new distribution agreements being signed. We continue to ramp up plasma collection at our Texas-based facilities in support of our new three-year, $50 million supply agreement and expect to commence plasma sales by year-end. Lastly, securing new business development and M&A opportunities remains a core focus, and as already said, we are committed to expanding our current commercial portfolio and accelerating our current double-digit organic growth. The underlying demand for our products, including for Kedrob in the U.S. market, as well as Varizig and Hepagam, continues to increase. Our lead product continues to be our anti-rabies immunoglobulin, Kedrob, which is being distributed in the U.S. through our collaboration with Cadrion. End-user utilization of the product in the U.S. is continuing to increase significantly and our product supply to Cadrion is increasing year over year and beyond Cadrion contractual minimum commitment. In addition to a significant market share in the U.S., we continue to grow sales of CamRub in leading international markets such as Canada, Latin America, and Israel. Glacia represents our second leading franchise with revenue contribution driven by our growing product sales in ex-US markets such as Argentina, Russia, Israel, Switzerland, as well as additional markets mainly in Latin America, as well as royalty income generated from sale of the product by Takeda in the US and Canada. We continue to support the comprehensive post-marketing research program for Cytogum The benefits of this program were recently highlighted by the presentation of data by Dr. Daniel Calabresi Assistant Professor of Medicine at the UCSF Lung Transplant Program at the 2026 International Society for Heart and Lung Transplant Annual Meeting. Findings presented by Dr. Calabresi based on analysis of CMV high-risk lung transplant recipients suggest cytogram use is associated with improved clinical outcomes supporting increased cytogram utilization. In addition, patients continue to be enrolled in the investigate-initiate trial titled the SHIELD study, which is prospective randomized controlled multicenter study in CMV high-risk kidney transplant recipients. The trial is investigating the benefit of cytogram administrated at the conclusion of antiviral prophylaxis to reduce the risk of clinically significant late CMV in kidney transplant recipients who are CMV seronegative and have a CMV seropositive donor. We believe that the data generated by this study will support increased product utilization for CytoGum in the large population of kidney transplant recipients. With respect to Varizig, our anti-varicella zuster immunoglobulin, and Hepagum, our hepatitis B immunoglobulin, we are experiencing strong market demand for these products resulting among other things from our product awareness activities in the U.S. market. As for distribution operation, as part of activities to advance organic growth, we already have two biosimilar products launched in the Israeli market and we are on track to launch two other products during this quarter. We have other biosimilar products in the pipeline to be launched in the coming years and additional in-licensing agreements are in process. We believe that this portfolio will become an increasingly important portion of a distribution business with biosimilar annual sales of between $15 million to $20 million within the next few years. We are also continuing to advance expansion of a distribution activity to the MENA region. We have recently entered into several distribution agreements and initiated activities to register the underlying products with local authorities. We continue to engage in discussion with additional international companies offering them full service from registration all the way to commercialization. In July, we were very pleased to announce our three-year, $50 million sales agreement, first of its kind, to supply normal source plasma to a leading biopharmaceutical company focused on plasma-derived therapies. This agreement validates our plasma collection strategy and the investment we made in our U.S.-based state-of-the-art plasma collection centers as well as our vertical integration strategy and multi-year revenue growth objectives. We expect that initial commercial sales on this agreement will be recorded in the fourth quarter of this year and have included these projected revenues in our current annual guidance. Moving to business development and M&A. We continue to evaluate opportunities to enrich our portfolio of marketed products and complement our existing commercial operations. This remains a core focus and we are committed to expanding our current commercial portfolio, accelerating our long-term profitable growth. With that, I turn the call over to Chaime for a detailed discussion of our financial results. Chaime, please go ahead.